ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Is the Concept of National Chain Of Outpatient Centers Still Viable?

May 2, 1997

WHT Participants Get “Phase Out” Help

March 11, 1988

In Brief: Kristian Storm Names Chief Of Surgical Oncology At Univ. Of Wisconsin; Skibba To Join CTEP

November 13, 1987

DCPC Board approves 7 New RFAs, 2 Pas

October 21, 1994

In Brief: Lame Ducks continue On NCAB; Calabresi Elected To IOM; Ravikumar Moves To Yale

September 28, 1990